相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
D. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma
Lauren C. Harshman et al.
CANCER INVESTIGATION (2009)
Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma
Ingrid Alexandre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule
Astrid A. M. van der Veldt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius et al.
LANCET (2009)
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib
Doru T. Alexandrescu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
Yuan Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Betty Y. Y. Tam et al.
NATURE MEDICINE (2006)
Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
Julia Bohlius et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Role of c-Kit and erythropoietin receptor in erythropoiesis
V Munugalavadla et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy
S Richard et al.
BLOOD (2002)